BioAdvance News Eliksa Therapeutics Portfolio News

Eliksa Therapeutics launched with University of Utah’s commercial and clinical-stage regenerative medicine technology

By WebmasterJuly 19, 2022November 1st, 2024No Comments

Eliksa Therapeutics launched with University of Utah’s commercial and clinical-stage regenerative medicine technology

Founding investors include Militia Hill Ventures and University of Utah

Previous PostKaloCyte Closes Investment from New York Blood Center
Next PostRenovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy